Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanosome degradation refers to the biological process by which **melanosomes**—specialized organelles responsible for the synthesis and storage of melanin in melanocytes—are broken down within cells. This process is primarily mediated by a form of selective autophagy known as **melanophagy**, where specific molecular machinery targets mature or damaged melanosomes for lysosomal destruction. Key components involved include E3 ubiquitin ligases (such as RCHY1), the autophagy receptor optineurin (OPTN), adaptor protein p62/SQSTM1, and regulatory kinases like TBK1. The pathway involves ubiquitination of the melanosome membrane proteins to mark them for recognition by these adaptors and subsequent engulfment by autophagosomes. Pharmacological agents such as β-mangostin, PTPD‑12, Melasolv, and marliolide derivatives have been shown experimentally to induce this pathway in vitro or in cell models. Modulation of this process can influence skin pigmentation without directly affecting melanogenesis gene expression; thus it is relevant both physiologically (for normal pigment turnover) and pathologically (in hyperpigmentation disorders). However, "melanosome degradation" itself is not a single molecular target but rather a cellular event/process involving multiple protein factors that could be considered individual therapeutic targets[1][2][3][5]. Because "melanosome degradation" describes a biological process rather than a discrete molecule or receptor suitable for direct drug targeting or classification alongside enzymes/receptors/transporters/etc., it should not be considered a canonical therapeutic target per se. Instead, its key mediators—such as OPTN or RCHY1—would be more appropriate entries if seeking structured information about druggable targets involved in this pathway. In summary: > “Melanosome degradation” is an important cellular mechanism regulating pigment homeostasis through selective organelle clearance but does not represent an individual molecular target; instead it encompasses several potential protein targets within its mechanistic cascade.[1][2][3]
Induction of selective autophagy targeting melanosomes for lysosomal degradation via ubiquitination and recruitment of autophagy receptors such as OPTN and p62[1][3][5]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melanosome degradation (null).